Clinical trials: Community Pneumonia
Sepsis, Community-acquired Pneumonia
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute
- Trial name
- NCT04612413
- Testing
- Allocetra-OTS
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- Enlivex Therapeutics Ltd.
Community-acquired Pneumonia
Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward
Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions.
- Trial name
- CAPTAIN (NCT06229288)
- Testing
- Amoxicillin, Amoxicillin/clavulanate
- Where
- 19 sites in France
- Volunteers
- 326 people
- Sponsor
- Nantes University Hospital
Community Acquired Pneumonia
Community-Acquired Pneumonia : Evaluation of Corticosteroids
Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is between 25 and 30% in sub-groups of patients.
- Trial name
- CAPE_COD (NCT02517489)
- Testing
- Hydrocortisone
- Where
- 32 sites in France
- Volunteers
- 952 people
- Sponsor
- University Hospital, Tours
Sars-CoV-2, Community-Acquired Pneumonia,COVID-19
EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA
Since end of December, a new coronavirus, close to the 2002 SARS coronavirus, cause serious pneumonias throughout world. There is currently no strong evidence of an efficient specific treatment.
- Trial name
- TEACHCOVID (NCT04347512)
- Testing
- Hydroxychloroquine and azithromycin treatment arm., Hydroxychloroquine, Control arm
- Sponsor
- University Hospital, Strasbourg, France
Pneumonia, Pneumonia, Viral
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
The goal of this prospective randomized study is to improve antibiotic use among hospitalized patients with suspected pneumonia.
- Conditions
- Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
- Trial name
- UP-CAPTAIn (NCT05976581)
- Testing
- Electronic alert, Structured communication of test results
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Jonathan Baghdadi
Pneumonia
Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)
The purpose of this study is to collect additional data on hospitalized Community-Acquired Pneumonia (CAP) on health states, health outcomes and on (health) resources and estimate the differences in the quality of life and…
- Trial name
- CHO-CAP (NCT00812084)
- Where
- Netherlands
- Volunteers
- 48,634 people
- Sponsor
- UMC Utrecht
Pneumonia, Diarrhea
Testing the Effectiveness of a Modified Community Model in Improving Child Health Outcomes in Mashonaland East, Zimbabwe
This study modified and contextualized a community mobilization approach in a bid to find a solution to reduce the high incidence and prevalence of child morbidity and mortality in Zimbabwe.The developed model will be tested for…
- Conditions
- Pneumonia, Diarrhea, Malnutrition, Fever
- Trial name
- NCT03176914
- Testing
- prevention and management of childhood illnesses at community level, conventional community interventions
- Where
- Zimbabwe
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- University of Zimbabwe
Gastroesophageal Reflux Disease (GERD), Community-acquired Pneumonia
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP).
- Trial name
- NCT02555852
- Testing
- esomeprazole, omeprazole, pantoprazole
- Where
- Canada
- Volunteers
- 4,238,504 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Community-acquired Pneumonia
Santeon-CAP; Dexamethasone in Community-acquired Pneumonia
The present study is designed to investigate the beneficial effects of adjunctive dexamethasone therapy in patients admitted with community-acquired pneumonia, additionally aiming at assessing what patients benefit from…
- Trial name
- NCT01743755
- Testing
- Dexamethasone
- Where
- 4 sites in Netherlands
- Volunteers
- 413 people
- Sponsor
- St. Antonius Hospital
Malaria, Pneumonia
Home Management of Malaria and Pneumonia
A well-implemented community-based program of early and appropriate treatment of fevers/malaria episodes and pneumonia,will improve child survival as measured by a reduction of the less than five mortality rate.
- Trial name
- HMM/P (NCT02151578)
- Testing
- home/community case management
- Where
- Burkina Faso
- Volunteers
- 11,500 people
- Sponsor
- World Health Organization
Community Acquired Pneumonia
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia
- Trial name
- NCT00270517
- Testing
- EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Pneumonia
IMPROVinG Outcomes in Community Acquired Pneumonia
Pneumonia is the commonest illness requiring hospitalization in Australia. Elderly patients account for most admissions and incur highest costs due to longer hospitalizations, higher readmission risks and poor functional…
- Trial name
- IMPROVe-GAP (NCT02835040)
- Testing
- New model of service delivery, Current practice
- Where
- 2 sites in Australia
- Volunteers
- 814 people
- Sponsor
- Western Health, Australia
Non-Severe Pneumonia, Under-Fives
ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia
Background: With documented rise in bacterial resistance in vitro to co-trimoxazole, there is a need to document in vivo effectiveness of the drug in treatment of non-severe pneumonia in the community setting.
- Conditions
- Non-Severe Pneumonia, Under-Fives, Children
- Trial name
- NCT00396526
- Testing
- Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
- Where
- India
- Volunteers
- 2,000 people
- Sponsor
- King George's Medical University
Anxiety, Depression
Improving Mental Health Among the LGBTQ+ Community
The overall aim of this program of research is to improve the mental health of people who identify as LGBTQ+ by increasing their social support through a brief intervention.
- Trial name
- NCT05540067
- Testing
- Acceptance-Based Behavior Therapy (ABBT), Treatment-as-Usual (TAU)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Brown University
Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
Innate Immune Response During Community Acquired Pneumonia
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics) many severe presentations of pneumonia…
- Conditions
- Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity
- Trial name
- ImPACT (NCT03379207)
- Testing
- Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid
- Where
- 3 sites in France
- Volunteers
- 258 people
- Sponsor
- University Hospital, Tours
Pulmonary Disease, Chronic Obstructive, Asthma
Smoking Cessation Intervention in Respiratory Inpatients
Prospective, open-label, parallel-group, 52-week trial comparing varenicline in combination with behavioral support with one session of behavioral support alone.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Asthma, Community Acquired Pneumonia
- Trial name
- NCT02922387
- Testing
- Varenicline, Behavioral support
- Volunteers
- 101 people
- Sponsor
- General Hospital of Kavala
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A Global Active Surveillance for Community Acquired Pneumonia
This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.
- Trial name
- NCT00929721
- Testing
- Blood draw, Chest X-ray, urine specimen
- Where
- Poland
- Volunteers
- 5,172 people
- Sponsor
- Pfizer
Heart Failure, Community Acquired Pneumonia
Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways
The aim of this study is to determine if by providing a collaborative, integrated pathway-based healthcare compared to the usual healthcare, whether or not this would be superior in reducing the length of hospital stay across…
- Conditions
- Heart Failure, Community Acquired Pneumonia, Venous Thromboembolism, Acute Kidney Injury
- Trial name
- CHAMP-Path (NCT01561885)
- Testing
- Pathway-Based Care
- Where
- Saudi Arabia
- Volunteers
- 341 people
- Sponsor
- Majed Aljeraisy
COVID-19
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings
CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and…
- Trial name
- CanTreatCOVID (NCT05614349)
- Testing
- Paxlovid, Antioxidant
- Where
- 6 sites in Canada
- Volunteers
- 797 people
- Sponsor
- Unity Health Toronto